Global Cancer Monoclonal Antibodies Market - 2019-2026
|出版日期||內容資訊||英文 190 Pages
|癌症單株抗體的全球市場:2019年∼2026年 Global Cancer Monoclonal Antibodies Market - 2019-2026|
|出版日期: 2020年09月30日||內容資訊: 英文 190 Pages||
The Global Cancer Monoclonal Antibodies market is expected to grow at a CAGR of 11.86% during the forecast period (2020-2027).
Monoclonal Antibodies are mono-specific antibodies bodies having identical immune cells which are clones of a single parent cell and are directed to specific cellular targets. Therefore, Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. Hence, monoclonal antibodies technology is proved to be more effective than other cancer therapies.
The market growth is driven by several factors such as the rising incidence of cancer patients and growing investments by the companies in the research and development of genomic studies. The market is also driven by the specificity of the nature of monoclonal antibodies to target only cancer cells. However, the market is negatively affected by the high costs involved in the development of these advanced techniques and regulatory issues faced by the countries for the rolling out of these products.
The largest part of cancer immunotherapies involved monoclonal antibodies as monoclonal antibodies having more potential to offer less toxic and efficient therapy to the patients. They are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer.
Based on antibodies, the market is segmented into Humanized, Murine, Rat, Chimeric, Human, Immunotoxin, Immunoadhesin, and Others.
Based on Applications, the market is segmented into Non-small-cell lung cancers, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Glioma cancer, Bladder Cancer, Lymphoma, Ovarian Cancer, and Others.
Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW.
North America dominates the global cancer monoclonal antibodies market due to the well-established healthcare infrastructures, increased spending by the government for infection control and management, and the rising prevalence of lifestyle-related diseases.
In 2015, the US government spent US 13.6 billion to execute the above-mentioned activities. This region is expected to show growth owing to the rise in funding by the government for cancer research and technology development.
Market Key Companies
The global Cancer Monoclonal Antibodies market share is divided majorly among ImmunoGen Inc, Spectrum Pharmaceuticals, Amgen Inc, Lifeline Scientific, Bristol-Meyer Squibb, GlaxoSmithKline, Roche Holding, Merck & Co. Inc., Seattle Genetics, and Novartis AG.
The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Key takeaways from this report
Visualize the composition of the Global Cancer Monoclonal Antibodies market across each indication, in terms of type and applications, highlighting the key commercial assets and players.
Identify commercial opportunities in Global Cancer Monoclonal Antibodies by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Global Cancer Monoclonal Antibodies market - level 4/5 segmentation
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
Product mapping in excel for the key Global Cancer Monoclonal Antibodies products of all major market players.